Literature DB >> 25162786

PharmGKB summary: gemcitabine pathway.

Maria L Alvarellos1, Jatinder Lamba, Katrin Sangkuhl, Caroline F Thorn, Liewei Wang, Daniel J Klein, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25162786      PMCID： PMC4189987          DOI： 10.1097/FPC.0000000000000086

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  64 in total

1.  Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.

Authors:  Raphaël Maréchal; Jean-Baptiste Bachet; John R Mackey; Cécile Dalban; Pieter Demetter; Kathryn Graham; Anne Couvelard; Magali Svrcek; Armelle Bardier-Dupas; Pascal Hammel; Alain Sauvanet; Christophe Louvet; François Paye; Philippe Rougier; Christophe Penna; Thierry André; Charles Dumontet; Carol E Cass; Lars Petter Jordheim; Eva-Laure Matera; Jean Closset; Isabelle Salmon; Jacques Devière; Jean-François Emile; Jean-Luc Van Laethem
Journal:  Gastroenterology       Date:  2012-06-13       Impact factor: 22.682

2.  Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.

Authors:  Amit K Mitra; Kristine R Crews; Stanley Pounds; Xueyuan Cao; Tanya Feldberg; Yogita Ghodke; Varsha Gandhi; William Plunkett; M Eileen Dolan; Christine Hartford; Susana Raimondi; Dario Campana; James Downing; Jeffrey E Rubnitz; Raul C Ribeiro; Jatinder K Lamba
Journal:  J Pharmacol Exp Ther       Date:  2011-06-28       Impact factor: 4.030

3.  A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.

Authors:  Christina H Wei; Tristan R Gorgan; David A Elashoff; O Joe Hines; James J Farrell; Timothy R Donahue
Journal:  Pancreas       Date:  2013-11       Impact factor: 3.327

4.  A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.

Authors:  Anjali S Advani; Mazyar Shadman; Francis Ali-Osman; Andrew Barker; Lisa Rybicki; Matt Kalaycio; Mikkael A Sekeres; Carlos M de Castro; Louis F Diehl; Joseph O Moore; Anne Beaven; Ed Copelan; Ronald Sobecks; Parisa Talea; David A Rizzieri
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-12

5.  Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells.

Authors:  Sumit Parmar; Angela Seeringer; Dina Denich; Franziska Gärtner; Kai Pitterle; Tatiana Syrovets; Barbara Ohmle; Julia C Stingl
Journal:  Pharmacogenomics       Date:  2011-04       Impact factor: 2.533

6.  Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.

Authors:  Soo-Youn Lee; Seock-Ah Im; Yeon Hee Park; Sook Young Woo; Seonwoo Kim; Moon Ki Choi; Wonjin Chang; Jin Seok Ahn; Young-Hyuck Im
Journal:  Eur J Cancer       Date:  2013-12-18       Impact factor: 9.162

7.  Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.

Authors:  V Heinemann; Y Z Xu; S Chubb; A Sen; L W Hertel; G B Grindey; W Plunkett
Journal:  Cancer Res       Date:  1992-02-01       Impact factor: 12.701

8.  FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

Authors:  Huadong Pei; Liang Li; Brooke L Fridley; Gregory D Jenkins; Krishna R Kalari; Wilma Lingle; Gloria Petersen; Zhenkun Lou; Liewei Wang
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

Review 9.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

Authors:  W Plunkett; P Huang; Y Z Xu; V Heinemann; R Grunewald; V Gandhi
Journal:  Semin Oncol       Date:  1995-08       Impact factor: 4.929

10.  Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?

Authors:  Matias E Valsecchi; Thomas Holdbrook; Benjamin E Leiby; Edward Pequignot; Susan J Littman; Charles J Yeo; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  BMC Cancer       Date:  2012-03-22       Impact factor: 4.430
View more
  22 in total

1.  Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.

Authors:  Stephanie N Dorman; Katherina Baranova; Joan H M Knoll; Brad L Urquhart; Gabriella Mariani; Maria Luisa Carcangiu; Peter K Rogan
Journal:  Mol Oncol       Date:  2015-08-22       Impact factor: 6.603

2.  Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.

Authors:  Abeer F Alharbi; Robert A Kratzke; Jonathan D'Cunha; Michael Anthony Maddaus; Kinjal Sanghavi; Mark N Kirstein
Journal:  Cancer Chemother Pharmacol       Date:  2018-12-12       Impact factor: 3.333

3.  Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review.

Authors:  Jeanne Allard; Mathilde Bonnet; Lucie Laurent; Mohamed Bouattour; Marie-Pauline Gagaille; Vincent Leclerc
Journal:  Eur J Clin Pharmacol       Date:  2022-05-04       Impact factor: 2.953

4.  Optimization of nanoemulsion containing gemcitabine and evaluation of its cytotoxicity towards human fetal lung fibroblast (MRC5) and human lung carcinoma (A549) cells.

Authors:  Nadiatul Atiqah Wahgiman; Norazlinaliza Salim; Mohd Basyaruddin Abdul Rahman; Siti Efliza Ashari
Journal:  Int J Nanomedicine       Date:  2019-09-09

5.  Externally Triggered Novel Rapid-Release Sonosensitive Folate-Modified Liposomes for Gemcitabine: Development and Characteristics.

Authors:  Mahmoud M Omar; Omiya Ali Hasan; Randa Mohammed Zaki; Nermin E Eleraky
Journal:  Int J Nanomedicine       Date:  2021-01-28

Review 6.  Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.

Authors:  Jimin Xu; Yu Xue; Richard Zhou; Pei-Yong Shi; Hongmin Li; Jia Zhou
Journal:  Med Res Rev       Date:  2020-12-05       Impact factor: 12.944

7.  Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells.

Authors:  Vivien Koh; Hsueh Yin Kwan; Woei Loon Tan; Tzia Liang Mah; Wei Peng Yong
Journal:  BMC Genomics       Date:  2016-12-22       Impact factor: 3.969

8.  Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.

Authors:  Justine M Grixti; Steve O'Hagan; Philip J Day; Douglas B Kell
Journal:  Front Pharmacol       Date:  2017-03-27       Impact factor: 5.810

9.  Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.

Authors:  Yasuhiro Tsume; Adam J Drelich; David E Smith; Gordon L Amidon
Journal:  Molecules       Date:  2017-08-10       Impact factor: 4.411

10.  Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Authors:  Beatrice Seddon; Sandra J Strauss; Jeremy Whelan; Michael Leahy; Penella J Woll; Fiona Cowie; Christian Rothermundt; Zoe Wood; Charlotte Benson; Nasim Ali; Maria Marples; Gareth J Veal; David Jamieson; Katja Küver; Roberto Tirabosco; Sharon Forsyth; Stephen Nash; Hakim-Moulay Dehbi; Sandy Beare
Journal:  Lancet Oncol       Date:  2017-09-04       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.